Conference Call Q3/2016 Results

Transcription

1 Conference Call Q3/206 Results Bad Homburg, 27 October 206 Frankfurt stock exchange: FRE US ADR program: FSNUY

2 Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation. Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 2

3 Fresenius Group: Q3/206 Highlights Acquisition of Quirónsalud creates European leader in hospital operations Fresenius Medical Care celebrates 20 th anniversary Acceleration of sales growth Strong earnings growth Group earnings guidance improved New mid-term targets in February 207 Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 3

4 Fresenius Group: Q3/206 Key Financials Sales EBIT Net Income m +7% +6% +0% 7,339, ,940, Q3/5 Q3/6 Q3/5 Q3/6 Q3/5 Q3/6 Constant currency growth rates 205 EBIT before special items Net income attributable to shareholders of Fresenius SE & Co. KGaA; 205 before special items Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 4

5 Fresenius Group: Profit and Loss Statement m Q3/206 Q3 YoY Q 3/206 Q 3 YoY Sales 7,339 7% 2,345 6% EBIT 2,082 6% 3,092 9% Net interest -42 2% % Income taxes % % Net income 2, %,54 5% Constant currency growth rates before special items 3 Net income attributable to shareholders of Fresenius SE & Co. KGaA For a detailed overview of special items please see the reconciliation tables on slides Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 5

6 Fresenius Group: Q3/206 Key Financials Organic sales growth EBIT growth in constant currency +7% +0% +5% +% +4% +6% +% +7% +6% +6% 205 EBIT before special items Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 6

7 Fresenius Kabi (/2) North America 2% organic sales growth in Q3/6 despite tough PY quarter Gradual easing of IV drug shortages: 6 Kabimarketed products currently designated in shortage vs. 7 at the end of Q2/6 6 product launches YTD; confirm top end of 6 to 0 target range for FY/6 Europe 3% organic sales growth in Q3/6 On track to meet outlook of low to mid single-digit organic sales growth for FY/6 Product Name Product Group Launch Date Amikacin Anti-infective Q Linezolid Anti-infective Q2 Chloramphenicol Anti-infective Q2 SmofLipid Lipid emulsion Q3 Daptomycin Anti-infective Q3 Ketorolac (pre-filled syringe) Analgesic Q3 Increase outlook: Low to mid single-digit organic sales growth for FY/6 (Previous: Low single-digit) Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 7

8 Fresenius Kabi (2/2) Emerging Markets China 9% organic sales growth in Q3/6 New tender rules: 0 out of 3 provinces have finalized tender process Expect low single-digit price impact in FY6 Sustainable double-digit volume growth expected Asia-Pacific ex China 0% organic sales growth in Q3/6 Latin America/Africa 7% organic sales growth in Q3/6 Emerging Markets overall On track to meet FY/6 outlook of likely low double-digit organic sales growth China tender situation: Applicable to Kabi s Pharmaceutical and Nutrition business New tender Xinjiang Tibet concluded before Q2/6 concluded since Q2/6 process launched rules published process not yet initiated Qinghai Gansu Sichuan Yunnan Inner Mongolia Shaanxi Guizhou Guangxi Shanxi Henan Hubei Hunan Hainan Beijing Hebei Anhui Jiangxi Heilongjiang Jilin Liaoning Tianjin Zhejiang Fujian Shanghai Disclaimer: This update is only intended to give a general picture of the drug purchase tendering status of each province / direct-controlled city in China. The status may vary between type of drugs, specific products or specific area /hospital. Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 8

9 Fresenius Kabi: EBIT m Q3/206 Q3 YoY Q 3/206 Q 3 YoY Europe 80-2% 243-3% Margin 5.4% -70 bps 5.5% -90 bps North America 26 7% 669 % Margin 39.9% 70 bps 4.% 220 bps Asia-Pacific/Latin America/Africa 94 % 245 8% Margin 2.0% 80 bps 9.4% 220 bps Corporate and Corporate R&D % % Total EBIT 300 % 96 7% Margin 9.9% -20 bps 20.6% 90 bps Constant currency growth rates 205 before special items Margin growth at actual rates For a detailed overview of special items please see the reconciliation tables on slides Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 9

10 Fresenius Helios Germany 4% organic sales growth in Q3/6 driven by admissions increase Ongoing favorable reimbursement environment: 207 DRG inflator set at 2.50% Quirónsalud Closing process and debt financing progressing On track to meet FY/6 outlook: Sales of 2.5 bn EBITDA of 460 to 480 m Sales m +4% +4% 4,67 4,382,393,470 Q3/5 Q3/6 Q 3/5 Q 3/6 Organic sales growth Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 0

11 Fresenius Helios: EBIT m Q3/206 Q3 YoY Q 3/206 Q 3 YoY Total sales,470 6% 4,382 5% EBIT Established clinic portfolio 74 5% 506 7% Margin 2.0% 20 bps.6% 30 bps Acquisitions / Divestitures (consolidation / deconsolidation < yr) Margin 6.3% % -- Total EBIT 75 6% 507 7% Margin.9% 0 bps.6% 30 bps 205 before special items For a detailed overview of special items please see the reconciliation tables on slides Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations

12 Fresenius Vamed % organic sales growth in Q3/6 reflects typical quarterly fluctuations of project business m Q3/ 206 Q 3/ 206 Continued strong order intake with good regional diversification Project business Service business 30 -% 325-2% 38 % 45 4% Total sales 268 0% 740 % Total EBIT 5 7% 3 3% Order intake 209 9% % Order,995 2% 2 backlog Project business only 2 Versus December 3, 205 Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 2

13 Fresenius Group: Cash Flow Operating CF Capex (net) Free Cash Flow m Q3/206 LTM Margin Q3/206 LTM Margin Q3/206 LTM Margin 3 6.2% % % 207.5% % % % % 9 9.8% Corporate/Other -3 n.a. -2 n.a. -5 n.a. Excl. FMC % % % % % % Before acquisitions and dividends 2 Margin incl. FMC dividend 3 Understated: 7.% excluding 5 million of capex commitments from acquisitions Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 3

14 Fresenius Group: 206 Financial Outlook by Business Segment Old New Sales growth organic 3% 5% 4% 6% EBIT growth (cc) 3% 5% 4% 6% Sales growth organic 3% 5% unchanged EBIT m unchanged Sales growth organic 5% 0% unchanged EBIT growth 5% 0% unchanged Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 4

15 Fresenius Group: 206 Financial Guidance Actual Old New Sales growth 27.6 bn 6% 8% unchanged constant currency Net income growth,423 m % 4% 2% 4% constant currency Net income attributable to shareholders of Fresenius SE & Co. KGaA; 205 before special items Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 5

16 Attachments Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 6

17 Financial results by business segment Q3/206 Q3 YoY Sales US$4,598 m 9% EBIT US$670 m 9% Sales,5 m % EBIT 300 m 0% Sales,470 m 6% EBIT 75 m 6% Sales 268 m 0% EBIT 5 m 7% 205 before special items For a detailed overview of special items please see the reconciliation tables on slides Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 7

18 Fresenius Group: Overview Calculation of Noncontrolling Interest m Q 3/206 FY/205 Earnings before tax and noncontrolling interest 2,659 3,262 Taxes Noncontrolling interest, thereof Fresenius Medical Care net income not attributable to Fresenius (Q 3/6: ~69%) Noncontrolling interest holders in Fresenius Medical Care (Q 3/6: US$27 m according to Fresenius Medical Care s Financial Statements) Noncontrolling interest holders in Fresenius Kabi (- 27 m), Fresenius Helios (- m), Fresenius Vamed (- m) and due to Fresenius Vamed s 23% external ownership (- 5 m) Net income attributable to Fresenius SE & Co. KGaA,54,358 Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 8

19 Fresenius Group: Cash Flow m Q3/206 LTM Margin Q3/205 LTM Margin YoY Operating Cash Flow % 900.3% 3.2% Capex (net) % % -3.8% Free Cash Flow (before acquisitions and dividends) % % -2.8% Acquisitions (net) Dividends Free Cash Flow (after acquisitions and dividends) % % -.7% Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 9

20 Fresenius Group: Cash Flow Operating CF Capex (net) Free Cash Flow m Q 3/206 LTM Margin Q 3/206 LTM Margin Q 3/206 LTM Margin % % % 437.5% % % % % 6 9.8% Corporate/Other -7 n.a. -5 n.a. -2 n.a. Excl. FMC, % % % 2 2, % %, % Before acquisitions and dividends 2 Margin incl. FMC dividend 3 Understated: 7.% excluding 5 million of capex commitments from acquisitions Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 20

21 Fresenius Group: Leverage Ratio 4, , Net Debt/EBITDA target 206 ~ , , Target 206 2,50 ~2.5 ~2.5 2,00 2,2 2,3,2,2,2,2,2,2, Q Q2 Q3 204 Q Q2 Q3 205 Q Q Q Pro forma acquisitions; before special items 2 Adjusted due to debt issuance cost restatement (U.S. GAAP standard ASU ) 3 Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG; before special items 4 Before special items before special items At annual average FX rates for both EBITDA and net debt Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 2

22 Fresenius Kabi: Organic Sales Growth by Product Segment m Q3/206 Organic Growth Q 3/206 Organic Growth IV Drugs 620 2%,87 5% Infusion Therapy 27 3% 636 5% Clinical Nutrition 403 7%,73 7% Medical Devices/ Transfusion Technology 27 7% 777 5% Total sales,5 5% 4,457 6% Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 22

23 Fresenius Kabi: Organic Sales Growth by Regions m Q3/206 Organic Growth Q 3/206 Organic Growth Europe 52 3%,569 2% North America 542 2%,628 5% Asia-Pacific 290 9% 82 8% Latin America/Africa 58 7% 439 6% Total sales,5 5% 4,457 6% Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 23

24 Fresenius Helios: Strong Sales Growth m Q3/206 Q3 YoY Q 3/206 Q 3 YoY Established clinic portfolio,454 4% 4,352 4% Acquisitions (consolidation < yr) 6 n.a. 30 n.a. Total Sales,470 6% 4,382 5% 205 before special items For a detailed overview of special items please see the reconciliation tables on slides Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 24

25 Fresenius Helios: Performance Indicators Q 3/206 Q 3/205 Change No. of hospitals 2 % - Acute care clinics % - Post-acute care clinics % No. of beds 34,70 34,076 2% - Acute care clinics 29,63 28,94 2% - Post-acute care clinics 5,088 5,62 -% Admissions - Acute care (inpatient) 923,34 89,654 4% Occupancy - Post-acute care 83% 83% Average length of stay (days) - Acute care 2 -Post-acute care December 3, German average (205): 7.3 Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 25

26 Fresenius Group: Key Figures According to IFRS Q 3/206 U.S. GAAP Q 3/206 IFRS Sales 2,345 2,65 EBIT 3,092 3,07 Net interest Net income adj.,54 2,3,2 Net income,54 2,8 2,3 Operating cash flow 2,259 2,273 Balance sheet total 44,075 44,39 Before special items relating to Fresenius Kabi s efficiency program of 3 million according to IFRS 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA 3 Net income attributable to shareholders of Fresenius SE & Co. KGaA after special items (IFRS) Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 26

27 Reconciliation according to U.S. GAAP Q3 206 / Q3 205 The Group s U.S. GAAP financial results as of September 30, 206 do not include special items, whereas the U.S. GAAP financial results as of September 30, 205 include special items. Net income attributable to shareholders of Fresenius SE & Co. KGaA was adjusted for these special items. The table below shows the special items and the reconciliation from net income (before special items) to earnings according to U.S. GAAP. m Q3/205 before special items efficiency program KABI integration costs for acquired Rhön hospitals disposal gains from two HELIOS hospitals Q3/205 according to U.S. GAAP (incl. special items) Sales 6,940 6,940 EBIT Interest result, ,03-46 Net income before taxes Income taxes Net income Noncontrolling interest Net income attributable to shareholders of Fresenius SE & Co. KGaA The special items are reported in the Group Corporate/Other segment. Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 27

28 Reconciliation according to U.S. GAAP Q / Q The Group s U.S. GAAP financial results as of September 30, 206 do not include special items, whereas the U.S. GAAP financial results as of September 30, 205 include special items. Net income attributable to shareholders of Fresenius SE & Co. KGaA was adjusted for these special items. The table below shows the special items and the reconciliation from net income (before special items) to earnings according to U.S. GAAP. m Q 3/205 before special items efficiency program KABI integration costs for acquired Rhön hospitals disposal gains from two HELIOS hospitals Q 3/205 according to U.S. GAAP (incl. special items) Sales 20,369 20,369 EBIT Interest result 2, , Net income before taxes Income taxes 2, , Net income Noncontrolling interest, , Net income attributable to shareholders of Fresenius SE & Co. KGaA, The special items are reported in the Group Corporate/Other segment. Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 28

29 Financial Calendar / Contact Financial Calendar Report on Fiscal Year Report on st quarter Annual General Meeting, Frankfurt/Main Report on 2 nd quarter Report on 3 rd quarter 207 Please note that these dates could be subject to change. Contact Investor Relations Fresenius SE & Co. KGaA phone: ir-fre@fresenius.com For further information and current news: Follow us on Twitter and LinkedIn: Q3/206 Results, 27 October 206, Fresenius SE & Co. KGaA Investor Relations 29